MicroTech Medical (Hangzhou) Co., Ltd.'s (HKG:2235) Price In Tune With Revenues

With a price-to-sales (or "P/S") ratio of 8.1x MicroTech Medical (Hangzhou) Co., Ltd. (HKG:2235) may be sending very bearish signals at the moment, given that almost half of all the Medical Equipment companies in Hong Kong have P/S ratios under 5.4x and even P/S lower than 1.9x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

See our latest analysis for MicroTech Medical (Hangzhou)

What Does MicroTech Medical (Hangzhou)'s Recent Performance Look Like?

With revenue growth that's superior to most other companies of late, MicroTech Medical (Hangzhou) has been doing relatively well. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.

Want the full picture on analyst estimates for the company? Then our free report on MicroTech Medical (Hangzhou) will help you uncover what's on the horizon.

Do Revenue Forecasts Match The High P/S Ratio?

The only time you'd be truly comfortable seeing a P/S as steep as MicroTech Medical (Hangzhou)'s is when the company's growth is on track to outshine the industry decidedly.

If we review the last year of revenue growth, the company posted a terrific increase of 36%. Pleasingly, revenue has also lifted 128% in aggregate from three years ago, thanks to the last 12 months of growth. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.

Turning to the outlook, the next three years should generate growth of 33% each year as estimated by the dual analysts watching the company. That's shaping up to be materially higher than the 24% each year growth forecast for the broader industry.

In light of this, it's understandable that MicroTech Medical (Hangzhou)'s P/S sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

The Final Word

While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.

We've established that MicroTech Medical (Hangzhou) maintains its high P/S on the strength of its forecasted revenue growth being higher than the the rest of the Medical Equipment industry, as expected. At this stage investors feel the potential for a deterioration in revenues is quite remote, justifying the elevated P/S ratio. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.

A lot of potential risks can sit within a company's balance sheet. Our free balance sheet analysis for MicroTech Medical (Hangzhou) with six simple checks will allow you to discover any risks that could be an issue.

If you're unsure about the strength of MicroTech Medical (Hangzhou)'s business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.